Reducing glucose variability with continuous subcutaneous insulin infusion is associated with reversal of axonal dysfunction in type 1 diabetes mellitus.
Adult
Axons
/ pathology
Blood Glucose
/ analysis
Diabetes Mellitus, Type 1
/ complications
Diabetic Neuropathies
/ drug therapy
Electrodiagnosis
Female
Glycated Hemoglobin
/ analysis
Humans
Hypoglycemic Agents
/ administration & dosage
Insulin
/ administration & dosage
Insulin Infusion Systems
Longitudinal Studies
Male
Middle Aged
Motor Neurons
Neurologic Examination
Neuroprotective Agents
Treatment Outcome
Young Adult
continuous subcutaneous insulin infusion
glycemic variability
nerve excitability
neuroprotection
type 1 diabetes mellitus
Journal
Muscle & nerve
ISSN: 1097-4598
Titre abrégé: Muscle Nerve
Pays: United States
ID NLM: 7803146
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
22
12
2018
revised:
30
09
2019
accepted:
09
10
2019
pubmed:
16
10
2019
medline:
31
3
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
We assess whether improvement in control of type 1 diabetes mellitus (T1DM) with continuous subcutaneous insulin infusion (CSII) can protect peripheral nerve function. Twelve patients with T1DM treated with multiple daily insulin injections were assessed with nerve excitability testing prior to and 3 months after initiation of CSII. Although commencing treatment with CSII for 3 months improved mean glycosylated hemoglobin, it did not significantly alter nerve excitability or glycemic variability (GV). In four patients, some deterioration in GV was observed, while eight patients had improvement in SD and mean amplitude of glycemic excursions. For these eight patients, there was normalization of depolarizing and hyperpolarizing threshold electrotonus and recovery cycle superexcitablity. When CSII initiation is able to reduce glycemic variability in T1DM, reversal of axonal dysfunction is seen, likely due to normalization of sodium-potassium pump function and restoration of transaxonal membrane potential.
Substances chimiques
Blood Glucose
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Neuroprotective Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
44-51Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Greene DA, Lattimer SA. Impaired energy utilization and Na-K-ATPase in diabetic peripheral nerve. Am J Physiol. 1984;246(4 Pt 1):E311-E318.
Kitano Y, Kuwabara S, Misawa S, et al. The acute effects of glycemic control on axonal excitability in human diabetics. Ann Neurol. 2004;56(4):462-467.
Kiernan MC, Isbister GK, Lin CSY, Burke D, Bostock H. Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Ann Neurol. 2005;57(3):339-348.
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
Martin CL, Albers JW, Pop-Busui R, DCCT/EDIC Research Group. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):31-38.
Sartore G, Chilelli NC, Burlina S, Lapolla A. Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013;50(3):437-442.
Kwai NCG, Arnold R, Poynten AM, Krishnan AV. Association between glycemic variability and peripheral nerve dysfunction in type 1 diabetes. Muscle Nerve. 2016;54(5):967-679.
Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type I diabetes. Diabetes Care. 1996 Apr;19(4):324-327.
Krishnan AV, Lin CSY, Park SB, Kiernan MC. Axonal ion channels from bench to bedside: A translational neuroscience perspective. Prog Neurobiol. 2009;31:1-26.
Kwai N, Arnold R, Poynten AM, Lin CSY, Kiernan MC, Krishnan AV. Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. Diabetes Metab Res Rev. 2015;31(2):175-182.
Bae JS, Kim OK, Kim JM. Altered nerve excitability in subclinical/early diabetic neuropathy: evidence for early neurovascular process in diabetes mellitus? Diabetes Res Clin Pract. 2011;91(2):183-189.
Arnold R, Kwai N, Lin CSY, Poynten AM, Kiernan MC, Krishnan AV. Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes Metab Res Rev. 2013;29(1):53-59.
Sung J-Y, Park SB, Liu Y-T, et al. Progressive axonal dysfunction precedes development of neuropathy in type 2 diabetes. Diabetes. 2012;61(6):1592-1598.
Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17(11):1281-1289.
Kiernan MC, Lin CSY, Excitability N. In: Aminoff MJ, ed. Aminoff's Electrodiagnosis in Clinical Neurology. St Louis, MO: Elsevier; 2012:345-365.
Frontoni S, Di Bartolo P, Avogaro A, Bosi E, Paolisso G, Ceriello A. Glucose variability: an emerging target for the treatment of diabetes mellitus. Diabetes Res Clin Pract. 2013;102(2):86-95.
Jin HY, Lee KA, Park TS. The impact of glycemic variability on diabetic peripheral neuropathy. Endocrine. 2016;53(3):643-648.
Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain. 2005;128(Pt 5):1178-1187.
Krishnan AV, Kiernan MC. Altered nerve excitability properties in established diabetic neuropathy. Brain. 2005;128(5):1178-1187.
Kiernan MC, Bostock H. Effects of membrane polarization and ischaemia on the excitability properties of human motor axons. Brain. 2000;123(Pt 12):2542-2551.
Baker MD, Bostock H. The pH dependence of late sodium current in large sensory neurons. Neuroscience. 1999;92(3):1119-1130.
Kiernan MC, Cikurel K, Bostock H. Effects of temperature on the excitability properties of human motor axons. Brain. 2001;124(Pt 4):816-825.
Kwai NCG, Arnold R, Poynten AM, et al. In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. Clin Neurophysiol. 2016;127(2):1700-1706.
Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9(1):36-45.
Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681-1687.
Wentholt IME, Kulik W, Michels RPJ, Hoekstra JBL, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008;51(1):183-190.